Litigation Details for STATE OF CONNECTICUT v. AUROBINDO PHARMA USA, INC. (E.D. Pa. 2017)
✉ Email this page to a colleague
STATE OF CONNECTICUT v. AUROBINDO PHARMA USA, INC. (E.D. Pa. 2017)
| Docket | ⤷ Subscribe | Date Filed | 2017-08-23 |
| Court | District Court, E.D. Pennsylvania | Date Terminated | 2024-04-19 |
| Cause | 15:1 Antitrust Litigation | Assigned To | Cynthia M. Rufe |
| Jury Demand | None | Referred To | |
| Parties | MAYNE PHARMA INC. | ||
| Patents | 9,187,405 | ||
| Attorneys | EDWARD T VASQUEZ | ||
| Firms | Office of the Tennessee Attorny General & Reporter | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in STATE OF CONNECTICUT v. AUROBINDO PHARMA USA, INC.
The small molecule drug covered by the patent cited in this case is ⤷ Subscribe .
Details for STATE OF CONNECTICUT v. AUROBINDO PHARMA USA, INC. (E.D. Pa. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2019-07-26 | 170 | Exhibit Ex A and attachments | the claims of U.S. Patent No. 9,187,405 (“the ‘405 patent”), the Novartis patent that is the subject…Corporation (“Novartis”) owns U.S. Patent No. 5,604,229 (“the ‘229 patent”), directed to the active ingredient…upon expiration of the ‘229 patent; WHEREAS, the ‘229 patent precludes the sale of a generic… WHEREAS, the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office determined…unpatentability of all of the claims of the ‘405 patent in a Final Written Decision issued on July 11, | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
